Tag Archive for: NIH
SBIR/STTR programs will expire if Congress doesn’t reauthorize by September 30th. Senator Paul blocked reauthorization because of security problems. New provisions added to address security concerns.
Bill passed Senate, expected to pass House. SBIR/STTR programs extended for three more years.
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.
NCI and CDMRP are awarding over $7 BILLION in funding for cancer R&D. To learn more, listen to our free webinar about these opportunities.
Find out about more than $7 Billion In Funding Opportunities for Cancer Research – and our webinar all about them
President Biden called on Congress to fund the creation of a new agency, a DARPA for Health. Some breakthrough ideas don’t receive sufficient attention because they are too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. The Advanced Research Projects Agency for Health (ARPA-H) aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will not have intramural labs. It will facilitate research directed at solving practical problems. To date, the kinds of non-dilutive funding opportunities which will be available through ARPA-H (grants, contracts, etc.) have not been defined, but we can make intelligent guesses.
Spending bill ends funding for Biden’s COVID-19 programs, including some R&D, but does provide more funding for biomedical research: $45 billion for NIH, including $1 billion for Advanced Research Projects Agency for Health (ARPA-H), and $8.5 billion for the CDC.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109